Cadherin 11: Function, Role in Disease, and Therapeutic Use

Cadherin-11 is a cell-adhesion protein that acts as a kind of molecular glue, helping certain cells stick to one another and communicate. It is expressed most prominently in connective tissue cells, including those that build bone, line joints, and populate scar-forming tissue. That dual life as both a normal tissue organizer and a driver of disease has made it one of the more closely watched molecules in rheumatology, fibrosis research, and oncology over the past two decades. Its story is not a simple “good protein gone bad” narrative, though. Understanding where cadherin-11 works normally explains why, when its expression goes awry, so many different organ systems can be affected.

What Cadherin-11 Actually Does in Healthy Tissue

Cadherin-11 (often abbreviated CDH11 or OB-cadherin) belongs to the classical cadherin family of adhesion molecules. Like other cadherins, it spans the cell membrane and sticks out on the cell surface, where it grabs onto matching cadherin-11 molecules on neighboring cells. Calcium ions wedge between the protein’s outer domains and stiffen the structure, giving the connection mechanical strength. On the inside of the cell, cadherin-11’s tail links up with a set of anchor proteins, including beta-catenin and alpha-catenin, that connect to the cell’s internal scaffolding.

This arrangement does more than just glue cells together. The intracellular portion of cadherin-11 contains a juxtamembrane domain that regulates how quickly alpha-catenin turns over at cell-cell contact points and how the actin scaffolding is organized. When that domain is deleted experimentally, cells ramp up a signaling molecule called Rac1 and build a thicker ring of internal structural fibers, and they lose the ability to rearrange and move past one another in multicellular clusters.¹ In other words, cadherin-11 is not just glue; it actively controls how cells move and remodel themselves.

Bone Formation and Skeletal Growth

Cadherin-11 was originally nicknamed “OB-cadherin” because it was first spotted on osteoblasts, the cells responsible for building new bone. Mice engineered to lack cadherin-11 develop lower bone density in the skull and in the spongy bone near the ends of long bones.² The protein is not absolutely required for a skeleton to form, but it steers precursor cells toward becoming bone-building osteoblasts rather than fat-storing adipocytes. Bone-marrow cells from cadherin-11-knockout mice show dramatically more fat accumulation, roughly ten-fold more fat-containing cells than wild-type cultures under the same conditions.³ So cadherin-11 acts like a toggle, favoring the bone-making program over fat storage in the cells that can do either.

Building and Maintaining the Synovium

If bone was cadherin-11’s first known home, the synovium, the thin tissue lining inside joints, turned out to be just as important. The synovial lining is made up largely of fibroblast-like synoviocytes, and cadherin-11 is the adhesion molecule that organizes these cells into a coherent lining layer. In three-dimensional culture experiments, blocking cadherin-11 with a fusion protein effectively prevented synoviocytes from forming a lining at all.⁴ Mice that lack cadherin-11 entirely develop an abnormally thin synovial lining and mount a disorganized inflammatory response when challenged, and they resist developing inflammatory arthritis.⁵

This finding created a paradox for researchers: the same molecule that builds a healthy joint lining also enables that lining to become dangerously aggressive in rheumatoid arthritis. The protein is not a villain or a hero; its role depends entirely on context.

How Cadherin-11 Drives Joint Destruction in Rheumatoid Arthritis

In rheumatoid arthritis, the synovial lining transforms into an inflamed, invasive tissue called pannus that eats into cartilage and bone. Cadherin-11 is heavily expressed in the fibroblast-like synoviocytes at the leading edge of that pannus tissue. In lab studies, blocking cadherin-11 with a fusion protein cut the number of invasive synoviocytes roughly in half compared to controls.⁶ The protein drives invasion through its intracellular juxtamembrane domain, the same region that controls cell rearrangement in healthy tissue.

Cadherin-11 also cranks up production of enzymes that chew through cartilage. When synovial fibroblasts are stimulated through cadherin-11, they increase output of matrix-degrading enzymes called MMP-1 and MMP-3. This effect works in concert with tumor necrosis factor alpha, one of the chief inflammatory signals in rheumatoid arthritis, making the combination more destructive than either signal alone.⁷ This cooperation with TNF-alpha is one reason researchers initially hoped that targeting cadherin-11 might complement existing anti-TNF therapies.

Fibrosis Across Multiple Organs

Fibrosis, the excessive buildup of scar tissue, is another arena where cadherin-11 plays a central and surprisingly consistent role. The common thread is the interaction between macrophages (immune cells that patrol tissues) and myofibroblasts (the cells that lay down scar-forming collagen). Cadherin-11 sits at the junction where these two cell types physically touch, and that contact activates a self-reinforcing loop of TGF-beta signaling, the master switch of fibrotic scarring.⁸

In the lungs, cadherin-11-deficient mice develop substantially less fibrosis in a standard bleomycin-induced model, and neutralizing antibodies against cadherin-11 reversed already-established lung fibrosis in the same model.⁹ In skin fibrosis models designed to mimic systemic sclerosis, cadherin-11 is upregulated on myofibroblasts in the deeper skin layers, and targeting it reduces the fibrotic process.¹⁰ In the heart after a heart attack, a cadherin-11-blocking antibody reduced inflammation-driven fibrotic remodeling and improved outcomes by limiting macrophage-driven production of the inflammatory signal IL-6 and promoting new blood-vessel formation.¹¹

The fact that the same mechanism, macrophage-myofibroblast adhesion through cadherin-11, seems to operate in lung, skin, heart, and kidney fibrosis makes this one of the more compelling examples of a shared disease pathway across organs.

Cancer, Metastasis, and the Cadherin Switch

During cancer progression, tumor cells often undergo a shift in which they trade their normal surface adhesion molecules for ones associated with mobile, invasive mesenchymal cells. Cadherin-11 is one of the key molecules that gets switched on during this transition. Tumor cells that gain cadherin-11 tend to become more invasive and more capable of spreading.¹²

The role is especially well-documented in cancers that spread to bone. Prostate cancer cells expressing cadherin-11 extend finger-like projections that intercalate directly into layers of osteoblasts, effectively using cadherin-11 as a molecular handshake that lets cancer cells physically lock onto bone-building cells.¹³ In Ewing sarcoma, a bone cancer that often affects adolescents, knocking down cadherin-11 reduced cell attachment and motility, and in animal models produced fewer metastases. In patients, cadherin-11 expression was significantly associated with bone metastases and worse overall survival.¹⁴

In the brain, cadherin-11 contributes to the aggressive migration of glioblastoma cells. Silencing cadherin-11 in glioblastoma cell lines reduced migration distance by over half, and it blocked the motility boost these cells normally get from TGF-beta stimulation.¹⁵¹⁶

Pancreatic cancer presents yet another angle. Here, cadherin-11 is expressed not so much by the cancer cells themselves but by the cancer-associated fibroblasts that surround and support the tumor. These fibroblasts deposit thick layers of scar-like tissue that act as a physical barrier to chemotherapy drugs and suppress the immune response. In a mouse model, reducing cadherin-11 levels extended survival significantly, and a small-molecule inhibitor of cadherin-11 shrank established tumors, but only when the mice had functioning immune systems, suggesting that cadherin-11 blockade works partly by lifting immunosuppression.¹⁷

Aortic Valve Calcification

One of the more recently explored roles of cadherin-11 involves calcific aortic valve disease, in which valve tissue stiffens and calcifies, eventually restricting blood flow from the heart. In calcified human aortic valves, the signaling molecule Rac1 is heavily upregulated and co-localizes with cadherin-11 to a far greater degree than the related molecule RhoA, roughly twice as much co-localization.¹⁸ Cadherin-11 appears to drive calcification by activating Rac1, which in turn pushes a key bone-forming transcription factor into the cell nucleus, essentially tricking valve cells into acting like osteoblasts. The irony here is clear: the same protein that promotes healthy bone formation in the skeleton can cause pathological bone-like deposits in the wrong tissue.

Neural Development and Autism

During embryonic development, cadherin-11 is expressed in neural crest cells, a migratory population that gives rise to parts of the face, peripheral nerves, and portions of the heart. In frog embryos, cadherin-11 is required for these cells to migrate collectively and in the right direction; impairing its adhesive function makes their migration disorganized and incomplete.¹⁹ This early developmental role suggests that mutations or dysregulation of cadherin-11 could have consequences for the formation of multiple organ systems.

In the brain specifically, cadherin-11 helps regulate the complexity of neuronal branching and synaptic signaling. Hippocampal neurons from cadherin-11-knockout mice develop overly complex branching patterns and show altered electrical activity. These mice also have elevated levels of excitatory synaptic markers, suggesting a shift toward excessive excitatory signaling. Human genetic studies have linked cadherin-11 to autism spectrum disorder, and the mouse findings offer a plausible mechanism: if cadherin-11 normally restrains dendritic complexity and excitatory synapse formation, its absence could produce the kind of hyper-connected circuits that some autism researchers hypothesize contribute to the condition.²⁰

Cadherin-11 as a Biomarker

Because cadherin-11 shows up so reliably in fibrotic and inflammatory tissue, researchers have explored whether measuring it in blood or urine could help diagnose or track disease without a tissue biopsy. In kidney disease, higher levels of cadherin-11 in both blood plasma and urine were associated with more severe fibrosis and scarring in kidney biopsies. Urinary cadherin-11 was independently associated with progression to end-stage kidney disease.²¹ The appeal is obvious: kidney biopsies are invasive and carry risks, and a urine test that could flag worsening fibrosis would be a meaningful clinical advance.

In pregnancy, cadherin-11 levels measured in the early second trimester may help predict preeclampsia, a dangerous condition involving high blood pressure and organ damage. Women who went on to develop preeclampsia had significantly higher cadherin-11 levels, and the predictive accuracy was strong, with an area under the curve above 0.88 for preeclampsia generally and above 0.90 for the early-onset form.²² These numbers are preliminary and come from a single study, but they suggest cadherin-11 could eventually join panels of early-pregnancy screening markers.

Therapeutic Targeting and the RG6125 Setback

Given its involvement in arthritis, fibrosis, and cancer, cadherin-11 seemed like a natural drug target. The most advanced attempt was RG6125, a monoclonal antibody designed to block cadherin-11, developed for rheumatoid arthritis patients who had not responded well to anti-TNF therapy.²³ The preclinical rationale was solid: in animal models, blocking cadherin-11 reduced arthritis, lung fibrosis, and skin fibrosis. But the phase 2 trial delivered a disappointing result. There was little to no difference between RG6125 and placebo on any of the primary or secondary measures of efficacy in patients already on anti-TNF drugs.²⁴

That failure has not closed the door on cadherin-11-directed therapy, but it has forced a rethink. One likely issue is patient selection: the trial recruited people already receiving anti-TNF drugs, and if TNF blockade already reduces some of the inflammatory signals that cooperate with cadherin-11, the added benefit of blocking cadherin-11 on top of that may be too small to detect. Another possibility is that cadherin-11’s contribution to joint destruction is more important in the early, tissue-remodeling phase of disease than in the chronic inflammatory phase that most clinical-trial participants are already in.

In cancer, the therapeutic angle is different. The pancreatic cancer data suggest that blocking cadherin-11 on fibroblasts surrounding tumors could make the immune system more effective and reduce resistance to chemotherapy. A small-molecule inhibitor of cadherin-11 shrank established pancreatic tumors in mice, but only when the animals had functional immune cells, pointing to an immunotherapy-adjacent mechanism rather than a direct anti-tumor effect.¹⁷ Whether this translates to human patients remains an open question, but the idea of targeting the tumor’s supportive stroma rather than the cancer cells themselves is attracting broad interest.

Why One Protein Matters in So Many Diseases

It can seem puzzling that a single adhesion molecule turns up in conditions as different as rheumatoid arthritis, lung fibrosis, pancreatic cancer, aortic valve calcification, and autism. The common thread is that cadherin-11 sits at the intersection of three things many diseases share: cell-to-cell adhesion, cytoskeletal remodeling, and signaling through pathways like Rac1 and TGF-beta. Whenever a disease involves abnormal tissue remodeling, whether that means invasive joint tissue, excessive scarring, a migrating tumor cell, or a misfiring neural circuit, cadherin-11 is likely part of the machinery. The protein is not the sole cause of any of these diseases, but it is a persistent enabler whose removal or blockade consistently dials down the pathological process in animal models.

The gap between animal models and human therapeutics, as the RG6125 trial demonstrated, remains real. But the breadth of cadherin-11’s involvement across tissues and diseases means researchers have many shots on goal. A drug that fails in late-stage rheumatoid arthritis might succeed in early-stage fibrosis or as part of a combination regimen in cancer. The biology is consistent enough across organs that each new finding in one disease informs the others, which is relatively unusual for a therapeutic target and keeps cadherin-11 firmly on the research radar.

Stromal Cells and the Tumor Microenvironment

One of the more interesting recent shifts in cadherin-11 research involves the non-cancer cells that surround a tumor. Invasive cancer cells upregulate cadherin-11 as part of the switch toward a mesenchymal phenotype, but the surrounding stromal cells, fibroblasts that are recruited by the tumor, also express it. When cancer cells and stromal cells both display cadherin-11, they physically adhere to one another, forming a supportive niche that helps the tumor grow and resist treatment.²⁵ This mirrors the macrophage-myofibroblast interaction seen in fibrotic tissues: cadherin-11 creates a physical bridge between two cell types whose cooperation drives disease.

The implication for therapy is that you do not necessarily have to kill the cancer cells to slow the disease. Disrupting the adhesive partnership between tumor cells and their stromal supporters could starve the tumor of structural and immunological protection. It also explains why cadherin-11 blockade worked in pancreatic cancer mice only when the immune system was intact: the drug was not killing cancer cells directly; it was peeling away the fibroblast shield so that immune cells could reach them.